Ep. 4 | Over a Decade Cancer-Free from Bladder Cancer, Driven by NK Cells, T-Cells and Immune Memory

This compelling presentation highlights a groundbreaking shift in treating non-muscle invasive bladder cancer (NMIBC) by addressing immune system collapse as the root cause of early mortality. The discussion centers on the long-term success of the Anktiva (N-803) plus BCG combination therapy, which enhances the body’s natural defenses by stimulating T-cells, NK cells, and crucial memory T-cells. Through powerful testimonials from patients who began trials as early as 2014, Dr. Patrick Soon-Shiong talks about the therapy’s remarkable durability with many participants remaining cancer-free for nearly a decade. By moving beyond traditional treatments that often lead to bladder removal, this “Cancer Bioshield” approach offers a life-affirming alternative that preserves organ function and restores patient longevity.